Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal medical therapy with or without PCI for stable coronary disease.
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Boden WE, et al. Among authors: knudtson m. N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26. N Engl J Med. 2007. PMID: 17387127 Free article. Clinical Trial.
The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Gau G, Weintraub WS; COURAGE Trial Co-Principal Investigators and Study Coordinators. Boden WE, et al. Among authors: knudtson m. Am J Cardiol. 2007 Jan 15;99(2):208-12. doi: 10.1016/j.amjcard.2006.07.082. Epub 2006 Nov 17. Am J Cardiol. 2007. PMID: 17223420 Clinical Trial.
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial.
Mancini GB, Bates ER, Maron DJ, Hartigan P, Dada M, Gosselin G, Kostuk W, Sedlis SP, Shaw LJ, Berman DS, Berger PB, Spertus J, Mavromatis K, Knudtson M, Chaitman BR, O'Rourke RA, Weintraub WS, Teo K, Boden WE; COURAGE Trial Investigators and Coordinators. Mancini GB, et al. Among authors: knudtson m. Circ Cardiovasc Qual Outcomes. 2009 Jul;2(4):320-7. doi: 10.1161/CIRCOUTCOMES.108.830091. Epub 2009 Jun 2. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031857 Clinical Trial.
Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK; COURAGE Trial Research Group. Maron DJ, et al. Among authors: knudtson m. J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58. doi: 10.1016/j.jacc.2009.10.062. J Am Coll Cardiol. 2010. PMID: 20338496 Free article. Clinical Trial.
Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB; Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators and Coordinators. Spertus JA, et al. Among authors: knudtson m. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):409-18. doi: 10.1161/CIRCOUTCOMES.113.000139. Epub 2013 Jul 9. Circ Cardiovasc Qual Outcomes. 2013. PMID: 23838107 Free PMC article. Clinical Trial.
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.
Mancini GB, Hartigan PM, Bates ER, Chaitman BR, Sedlis SP, Maron DJ, Kostuk WJ, Spertus JA, Teo KK, Dada M, Knudtson M, Berman DS, Booth DC, Boden WE, Weintraub WS. Mancini GB, et al. Among authors: knudtson m. Am Heart J. 2013 Sep;166(3):481-7. doi: 10.1016/j.ahj.2013.07.007. Epub 2013 Aug 2. Am Heart J. 2013. PMID: 24016497 Clinical Trial.
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424.
Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS; COURAGE trial coprincipal investigators and study coordinators. Boden WE, et al. Among authors: knudtson m. Am Heart J. 2006 Jun;151(6):1173-9. doi: 10.1016/j.ahj.2005.08.015. Am Heart J. 2006. PMID: 16781214
A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Tardif JC, L'Allier PL, Grégoire J, Ibrahim R, McFadden G, Kostuk W, Knudtson M, Labinaz M, Waksman R, Pepine CJ, Macaulay C, Guertin MC, Lucas A. Tardif JC, et al. Among authors: knudtson m. Circ Cardiovasc Interv. 2010 Dec;3(6):543-8. doi: 10.1161/CIRCINTERVENTIONS.110.953885. Epub 2010 Nov 9. Circ Cardiovasc Interv. 2010. PMID: 21062996 Clinical Trial.
Exploring the treatment-risk paradox in coronary disease.
McAlister FA, Oreopoulos A, Norris CM, Graham MM, Tsuyuki RT, Knudtson M, Ghali WA; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. McAlister FA, et al. Among authors: knudtson m. Arch Intern Med. 2007 May 28;167(10):1019-25. doi: 10.1001/archinte.167.10.1019. Arch Intern Med. 2007. PMID: 17533204
294 results